OR WAIT null SECS
Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.
Relmada Therapeutics just completed their phase II adjunctive major depressive disorder trial for their new medication dextromethadone (REL-1017), where they observed statistically significant anti-depressant effects, a favorable safety profile, and favorable tolerability. Maurizio Fava, MD, discusses the results and need-to-know information for REL-1017.
Dr Fava is chief of psychiatry at Massachusetts General Hospital and director of the division of clinical research for Massachusetts General Research Institute.